Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation

@inproceedings{Ozaki2020RealWorldAA,
  title={Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation},
  author={Aya F. Ozaki and A. Choi and Quang Thuu Le and Dennis T. Ko and Janet K. Han and Sandy Park and Cynthia A. Jackevicius},
  booktitle={Circulation. Cardiovascular quality and outcomes},
  year={2020}
}
Supplemental Digital Content is available in the text. Background: Stroke reduction with direct oral anticoagulants (DOACs) in atrial fibrillation (AF) is dependent on adherence and persistence in the real-world setting. Individual study estimates of DOAC adherence/persistence rates have been discordant. Our aims were to characterize real-world observational evidence for DOAC adherence/persistence and evaluate associated clinical outcomes in patients with AF. Methods and Results: PubMed, EMBASE… 

Figures from this paper

Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis
TLDR
A network meta-analysis of real-world evidence comparing adherence, persistence, cost, and utilization between oral anticoagulant (OAC) in non-valvular atrial fibrillation (NVAF) patients can raise awareness and understanding ofreal-world persistence associated with OAC therapy in NVAF patients.
Adherence to oral anticoagulation in ischemic stroke patients with atrial fibrillation
TLDR
Adherence was poor in half of AF patients who survived an ischaemic stroke, and the findings support the importance of recognising adherence support as a crucial part of holistic patient care recommended by recent AF guideline.
Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA
TLDR
Differences in anticoagulation treatment persistence across OAC agents, even after accounting for clinical events after OAC initiation are suggested, especially as non-persistence to OAC therapy is associated with thromboembolic complications.
Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008–2015)
TLDR
Dabigatran had the highest proportion of discontinuers and switchers at 12 months in most databases (EMA/2015/27/PH) and Apixaban was the DOAC with the highest persistence.
Association of income and educational levels with adherence to direct oral anticoagulant therapy in patients with incident atrial fibrillation: A Finnish nationwide cohort study
TLDR
It is observed that income and educational levels both have independent positive association on the implementation of DOAC therapy but no association on therapy persistence in patients with AF.
Anticoagulant prescribing for atrial fibrillation and risk of incident dementia
TLDR
Investigating the association between oral anticoagulant type and incident dementia or mild cognitive impairment among patients with newly diagnosed atrial fibrillation found incident EHR-recorded dementia and MCI were less common among patients prescribed DOACs for new AF compared with those prescribed VKAs.
Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation
  • J. Farinha, I. Jones, G. Lip
  • Medicine
    European heart journal supplements : journal of the European Society of Cardiology
  • 2022
TLDR
Factors influencing patient adherence and persistence to NOACs and possible problem solving strategies, especially involving an integrated care management, are discussed, aiming for the improvement in patient outcomes and treatment satisfaction.
Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy
TLDR
Reassurance is provided to practicing physicians that DOAC use appears to be effective in stroke prevention and is likely safer in RW patients than in RCT enrolled patients and a lower proportion of DOAC discontinuers was observed in the real-world than in pivotal RCT settings.
...
...

References

SHOWING 1-10 OF 87 REFERENCES
Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration
TLDR
In a real-world VA population being prescribed anticoagulation for AF, more than one quarter had sub-optimal adherence, and lower adherence was associated with a higher risk of mortality and stroke.
Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands
TLDR
It was demonstrated that secondary adherence was high in this specific setting among patients with at least two initial dispensations of a NOAC covering a minimum of 180 days, and the use of NOACs in a once daily regimen showed higher adherence compared to a twice daily regimen.
Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation.
TLDR
Nonadherence to dabigatran was common among patients with atrial fibrillation and future studies are needed to understand the reasons for nonadherence.
Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
  • J. Beyer‐Westendorf, B. Ehlken, T. Evers
  • Medicine
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2016
TLDR
Male gender and the presence of diabetes mellitus were associated with increased persistence, while renal impairment and antiplatelet drug use decreased persistence, and rivaroxaban was associated with better persistence and adherence than dabigatran.
Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.
TLDR
Among NVAF patients, rivaroxaban was associated with significantly higher adherence rates relative to other OACs whether using either a PDC of > 0.80 or >0.90, which could translate into improved patient outcomes and lower health care costs.
Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation
TLDR
Adherence to anticoagulation is poor in practice and may be modestly improved with NOACs, whereas the benefits of antICOagulation may not outweigh the harms in patients with CHA 2 DS 2‐VASc score 0 or 1.
Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.
TLDR
Clinicians and managed care organizations should consider the implications of lower adherence on clinical outcomes and quality assessment in patients with nonvalvular atrial fibrillation and rivaroxaban users with higher odds of high adherence among the NOACs in adjusted analyses.
Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience
TLDR
Persistence with NOAC drugs in patients with AF appears to be superior to warfarin, and if continued long-term, this alone will be of clinical importance in the prevention of stroke and death.
...
...